Inhibrx Biosciences (INBX) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Maze Therapeutics is the larger company by market cap ($1.46 billion vs $1.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | MAZE |
|---|---|---|
| Share price | $93.36 | $26.25 |
| Market cap | $1.37B | $1.46B |
| 1-day change | -0.05% | -0.68% |
| YTD return | — | -36.64% |
| 1-year return | — | -5.78% |
| EPS (TTM) | $-8.88 | $-2.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $155.29 | $53.65 |
| 52-week low | $28.16 | $21.95 |
| Distance from 52-week high | -39.88% | -51.07% |
| Average volume | 296.25K | 564.54K |
| Shares outstanding | 14.72M | 55.55M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
INBX vs MAZE FAQ
Which is bigger, Inhibrx Biosciences or Maze Therapeutics?
Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.46B compared with $1.37B for Inhibrx Biosciences (INBX).
Are Inhibrx Biosciences and Maze Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.